Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J., Aug. 31, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705/HPX2008).

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ) Darzalex for previously untreated patients with multiple myeloma. The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Velcade (bortezomib) plus thalidomide and dexamethasone given to patients before a stem cell transplant.

UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma

American Express

Bonanza Creek Energy

Salesforce

Dow Inc

Goldman Sachs

Home Depot

JPMorgan Chase & Co

Perion Network

Procter & Gamble

Travelers

UnitedHealth Group

Visa

Two new Breakout Stocks for Week 35 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +49.8% YTD with a record 20 out 34 weeks this year in negative signal conditions above the 40 MG level.

Week 35 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

Brookfield Renewable Partners

Innovative Industrial Properties

They offer more than just great dividends.

3 Dividend Stocks You Probably Will Never Regret Buying

American Water Works

Teladoc

These stocks could grow exponentially in coming years.

4 Top Stocks to Buy and Hold for the Next Decade

A federal judge has allowed Johnson & Johnson (NYSE: JNJ) to offload liabilities stemming from baby powder lawsuits. US bankruptcy judge Laurie Selber Silverstein made the ruling Thursday in Delaware, Reuters reported.

US Judge Allows Johnson & Johnson To Split Talc Powder Liabilities Into New Company

McDonald's

This trio of well-regarded dividend stocks should be considered as foundation pieces for an investor's retirement portfolio. The post 3 Top-Quality Dividend Stocks for a Secure Retirement appeared first on InvestorPlace.

3 Top-Quality Dividend Stocks for a Secure Retirement

Altria

PepsiCo

Walgreens

Taking a look at defensive names, which ones look like solid buys at current prices? These seven, mostly in the consumer staple and healthcare sectors, may be some of the best opportunities right now among safe stocks.

7 Safe Stocks To Buy for an Increasingly Unstable World

A federal judge has cleared the way for Johnson & Johnson to split its talc-related liabilities from the rest of its business, a decision that could allow the drugmaker to move thousands of claims by people who used its Baby Powder and other talc products into bankruptcy.

Judge allows Johnson & Johnson to split talc liabilities from main business

NEW BRUNSWICK, N.J., Aug. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award.

Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design

The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.

J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab

Johnson & Johnson (NYSE: JNJ) announced recently a change in leadership with Alex Gorsky stepping down from his CEO role and handing the reigns to Joaquin Duato, who will take over on Jan. 3, 2022. Here are five things you might not know about Joaquin Duato, the next CEO of Johnson & Johnson.

5 Things You Might Not Know About New Johnson & Johnson CEO Joaquin Duato

NEW BRUNSWICK, N.J., Aug. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28 th.

Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference

These are Insider's biggest healthcare stories for August 26.

J&J vaccine update - New booster timeline? - Clinical trial recruitment tech falls short

Pfizer

Better Healthcare Stock: Johnson & Johnson vs. Pfizer

AbbVie

And there's more than just dividends to like with these big pharma stocks.

3 Pharma Stocks to Buy With Juicy Dividends

On Wednesday, both Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) shares edged lower to extend this week's declines despite reporting positive developments.  On Monday, the Pfizer/BioNTech covid-19 vaccine received full approval from the US Food and Drug Administration for use on people aged 16 years and over.

What's the better stock to buy: Pfizer or J&J?

Agios Pharmaceuticals

Exelixis

Moderna

Novavax

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

On the heels of the first Covid-19 vaccine to receive approval from the U.S. Food and Drug Administration (FDA), Johnson & Johnson (NYSE:JNJ) announced some upbeat early-stage clinical trial news.

Options Bulls Bet on Johnson & Johnson Stock After Vaccine Update

According to interim data from two early-stage trials, a COVID-19 booster shot from Johnson & Johnson (NYSE: JNJ) sharply increased levels of antibodies. A second dose of the J&J single-dose vaccine resulted in binding antibody levels nine times higher than the levels 28 days after receiving their first dose.

Johnson & Johnson COVID-19 Booster Shot Generates 9X Spike-Binding Antibodies, Early Data Shows

Johnson & Johnson says it will submit the data to the FDA and meet with officials to discuss giving a COVID-19 booster shot after eight months.

J&J says a booster shot of its one-dose COVID-19 vaccine raises antibody levels, and could be given after 8 months

Johnson & Johnson said the booster generated a “rapid and robust” increase in antibodies nine times higher than seen four weeks after the vaccine's first and only dose was given.

Second Booster Shot Of Johnson & Johnson Covid Vaccine Provokes Strong Immune Response, Company Says

Amazon

2 Stocks to Help You Build Retirement Wealth

The drugmaker said early Wednesday that interim data from two new trials of its Covid-19 vaccine showed that a booster dose of the one-shot vaccine dramatically increased the immune response in patients.

J&J's Covid Booster Shot Increases Antibodies, Early Trials Show

Shares of Johnson & Johnson JNJ, -1.25% gained 0.8% in premarket trading on Wednesday after the company shared interim clinical data that indicates Americans who have received its single-dose COVID-19 vaccine should get a second dose. J&J said in a news release that two Phase 1/2a studies examining people who had received its shot found that a second dose boosted antibody levels.

News for Johnson & Johnson Stock (JNJ)